Please login to the form below

Not currently logged in
Email:
Password:

Vivus secures USD 140m milestone payment

US-based pharmaceutical company Vivus has secured a USD 140m milestone payment from co-development partner KV Pharmaceutical related to the rights for menopause treatment Evamist (transdermal estrogen).

US-based pharmaceutical company Vivus has secured a USD 140m milestone payment from co-development partner KV Pharmaceutical related to the rights for menopause treatment Evamist (transdermal estrogen).

KV licensed the rights for Evamist from Vivus and the drug has received FDA marketing approval.

Vivus, which also received a USD 10m upfront payment in May 2007, when it transferred the rights, revealed it was eligible for two additional one-time milestone payments worth USD 30m in total based on sales milestones for Evamist.

On a pro forma basis, including the milestone, the company's cash and cash equivalents at June 30 would have been USD 193.2m.

At a press meeting, Leland Wilson, Vivus' president and CEO said: "With the receipt of the milestone payment from KV, I believe Vivus is in the strongest financial position in our history. We estimate that we can fully fund the phase III trials of Qnexa (formerly VI-0521) for obesity and maintain a strong cash position at the end of those trials."

In pre-market trading, Vivus' shares rose USD 0.11 to rest at USD 5.86.

10th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics